Swiss National Bank increased its holdings in shares of Cryolife Inc (NYSE:CRY) by 13.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 54,100 shares of the medical equipment provider’s stock after purchasing an additional 6,400 shares during the period. Swiss National Bank owned 0.16% of Cryolife worth $1,036,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its holdings in Cryolife by 4.3% during the second quarter. The Manufacturers Life Insurance Company now owns 25,737 shares of the medical equipment provider’s stock worth $513,000 after purchasing an additional 1,054 shares during the period. Monarch Partners Asset Management LLC boosted its holdings in shares of Cryolife by 24.9% during the fourth quarter. Monarch Partners Asset Management LLC now owns 22,730 shares of the medical equipment provider’s stock worth $435,000 after acquiring an additional 4,530 shares during the period. KBC Group NV boosted its holdings in shares of Cryolife by 63.0% during the third quarter. KBC Group NV now owns 13,447 shares of the medical equipment provider’s stock worth $305,000 after acquiring an additional 5,197 shares during the period. Great West Life Assurance Co. Can boosted its holdings in shares of Cryolife by 13.4% during the third quarter. Great West Life Assurance Co. Can now owns 44,775 shares of the medical equipment provider’s stock worth $1,005,000 after acquiring an additional 5,284 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Cryolife by 9.3% during the third quarter. Rhumbline Advisers now owns 62,599 shares of the medical equipment provider’s stock worth $1,421,000 after acquiring an additional 5,308 shares during the period. Institutional investors and hedge funds own 73.99% of the company’s stock.
A number of equities research analysts have recently issued reports on CRY shares. Canaccord Genuity restated a “buy” rating and set a $28.00 price objective (up previously from $25.00) on shares of Cryolife in a report on Friday, March 9th. Northland Securities reiterated a “buy” rating and issued a $23.50 price target on shares of Cryolife in a research note on Thursday, March 8th. ValuEngine cut Cryolife from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Finally, Zacks Investment Research upgraded Cryolife from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Cryolife has an average rating of “Hold” and a consensus target price of $25.83.
Shares of Cryolife stock traded down $0.05 during mid-day trading on Thursday, hitting $20.45. The company had a trading volume of 36,673 shares, compared to its average volume of 107,731. The company has a current ratio of 4.18, a quick ratio of 3.09 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $690.90, a PE ratio of 51.63 and a beta of 0.75. Cryolife Inc has a fifty-two week low of $14.02 and a fifty-two week high of $24.00.
Cryolife (NYSE:CRY) last announced its quarterly earnings data on Wednesday, March 7th. The medical equipment provider reported $0.11 EPS for the quarter, meeting the consensus estimate of $0.11. Cryolife had a net margin of 1.95% and a return on equity of 5.93%. The business had revenue of $52.80 million during the quarter, compared to the consensus estimate of $48.40 million. During the same period in the previous year, the business earned $0.09 earnings per share. The company’s revenue was up 17.3% on a year-over-year basis. equities research analysts predict that Cryolife Inc will post 0.09 earnings per share for the current fiscal year.
In other Cryolife news, Director C Elkins Ronald sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $22.00, for a total transaction of $44,000.00. Following the completion of the transaction, the director now directly owns 97,849 shares in the company, valued at $2,152,678. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.00% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Swiss National Bank Has $1.04 Million Position in Cryolife Inc (NYSE:CRY)” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/22/swiss-national-bank-boosts-holdings-in-cryolife-inc-cry.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.